[1] 岳嘉宁, 符伟国. 肿瘤源性VTE事件的临床处置思路[N].中国医学论坛报, 2013-10-10(C12).
[2] 崔英, 吴淑花, 孙继红. 临床护士对深静脉血栓形成的认识及预防护理现状调查[J]. 护理研究, 2009, 23(9B): 2374-2376.
[3] 董梅. 消化系恶性肿瘤易合并血栓性疾病[N]. 中国医学论坛报, 2014-1-8(C12).
[4] Anderson JA,Weitz JI. Hypercoagulable states[J]. Crit Care Clin, 2011, 27(4): 933-952.
[5] Debaugnies F, Azerad MA, Noubouossié D, et al. Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay[J]. Thromb Res, 2010, 126(6): 531-535.
[6] 邓跃林. 急性肺栓塞的规范化诊疗——英国最新的肺栓塞指南[C]. 第二届中青年医师急危重症论坛论文汇编, 2008: 12-15.
[7] Linnemann B,LindhoffLast E.Risk factors,management and primary prevention of thrombotic complications related to the use of central venous catheters[J]. Vasa, 2012, 41(5): 319-332.
[8] De Pietri L, Montalti R, Beqliomini B, et al. Thromboelastographic changes in liver and pancreatic cancer surgery: hypercoagulability, hypocoagulability or normocoagulability?[J]. Eur J Anaesthesiol, 2010, 27(7): 608-616.
[9] Saccullo G, Malato A, Raso S, et al. Cancer patients requiring interruption of longterm warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed subtherapeutic doses of lowmolecular weight heparin[J]. Am J Hematol, 2012, 87(4): 388-391.
[10] 肖恭卫, 彭小东. 恶性肿瘤并肺栓塞198例临床分析[J]. 实用临床医学, 2010, 11(6): 12-14.
[11] Tormoen GW, Haley KM, Levine RL, et al. Do circulating tumor cells play a role in coagulation and thrombosis?[J]. Front Oncol, 2012, 2: 115.
[12] 曾福仁, 凌洋, 龚奎玉, 等. 恶性肿瘤患者血小板聚集及胞浆游离钙变化[J].中国现代医生, 2010, 48(18): 4-5.
[13] 黄希芬, 裴文仲. D二聚体在恶性肿瘤预后中的意义[J]. 实用心脑肺血管病杂志, 2009, 17(8): 704-705.
[14] 余鑫, 余昌俊, 余康敏, 等. CD62P、CD63、D二聚体与下肢深静脉血栓形成的关系[J]. 安徽医科大学学报, 2011, 46(4): 379-381.
[15] Braun OO, Johnell M, Varenhorst C, et al. Greater reduction of platelet activation markers and plateletmonocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease[J]. Thromb Haemost, 2008, 100(4): 626-633.
[16] 戴武, 韩晓芳, 叶山东, 等. 2型糖尿病患者糖耐量正常一级亲属SLE及sVCAM-1变化与胰岛素抵抗的相关性研究[J]. 安徽医科大学学报, 2009, 44(5): 640-642.
[17] Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism[J]. Thromb Res, 2010, 125(6): 511512.
[18] 邹丽芳, 姚一芸, 程毅敏, 等. 恶性肿瘤患者抗凝治疗前后止凝血功能的改变[J]. 血栓与止血学, 2011, 17(2): 69-72.
[19] 张路, 白春梅. 肿瘤患者静脉血栓栓塞治疗进展[J]. 癌症进展杂志, 2009, 7(1): 23-27.
[20] Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer[J]. N Eng J Med, 2002, 346(13): 975-980.
[21] 曲爱忠, 于秀丽, 付永兴. 高凝状态肿瘤患者抗凝联合化疗的临床观察[J]. 医学与哲学, 2013, 34(7B): 54-56.
[22] 王生, 赵杨, 陶丽, 等. 靶向纤溶系统活血化瘀药的抗肿瘤活性研究进展[J].中草药, 2012, 43(6): 1213-1218.
|